Adoption of Over-the-Counter Malaria Diagnostics in Africa: The Role of Subsidies, Beliefs, Externalities, and Competition



Plans for the wide-scale distribution and subsidy of artemisinin combination therapies (ACTs), an antimalarial treatment, pose two problems for public health planning. First, many people seeking malaria treatment do not have the disease. If ACT subsidies could be targeted toward those with malaria, the cost of subsidies could fall. Second, the inappropriate use of antimalarial drugs may contribute to the emergence of drug-resistant parasites. Rapid diagnostic tests (RDTs) for malaria could help with both problems, but drug shop owners may have few financial incentives to sell them, given profits from overtreatment for malaria. A model of the provision of RDTs by profit-maximizing drug shops shows that if all parties know the probability of having malaria and if there are no subsidies for drugs and no external costs to inappropriate treatment, both monopolistic and competitive drug shop owners will provide RDTs under the same circumstances that a social welfare maximizing planner would. However, since drugs will be subsidized, customers overestimate their likelihood of having malaria, and since there are external costs to the misuse of antimalarials, profit-maximizing drug shops will likely underprovide RDTs. We show that a subsidy for RDTs can increase provision and, under adequate competition, induce everyone to use RDTs optimally. The results also highlight the importance of educating customers about the true prevalence of malaria and promoting competition among drug providers.


Malaria Rapid diagnostic tests Antimalarial subsidies Markets for information Retail sector Drug resistance 


  1. ACT Watch. (2010). ACTwatch: Evidence for malaria medicines policy.
  2. Advaryu, A. (2012). Learning, misallocation, and technology adoption: Evidence from new malaria therapy in Tanzania, Mimeo. Yale School of Public Health. Available at
  3. Arrow, K., Panosian, C., & Gelband, H. (Eds.). (2004). Saving lives, buying time: Economics of malaria drugs in an age of resistance. Washington, DC: Institute of Medicine, National Academies Press.Google Scholar
  4. Cohen, J., Dupas, P., & Schaner, S. (2010). Prices, diagnostic tests, and the demand for malaria treatment, Mimeo. Harvard School of Public Health.Google Scholar
  5. Cohen, J., Dupas, P., & Schaner, S. (2012). Price subsidies, diagnostic tests, and targeting of malaria treatment: Evidence from a randomized controlled trial. National Bureau of Economic Research Working Paper #17943.Google Scholar
  6. Gentzkow, M. and Shapiro, J.M. 2006. Media Bias and Reputation. Journal of Political Economy. 114(2).Google Scholar
  7. Kachur, P., et al. (2006). Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania. Tropical Medicine and International Health, 11(4), 441–451.CrossRefGoogle Scholar
  8. Perkins, M., & Bell, D. (2008). Working without a blindfold: The critical role of diagnostics in malaria control. Malaria Journal, 7(Suppl I), S5.CrossRefGoogle Scholar
  9. Rafael, M., et al. (2006). Reducing the burden of childhood malaria in Africa: The role of improved diagnostics. Nature, 444(Suppl 1), 39–48. doi: 10.1038/nature05445.CrossRefGoogle Scholar
  10. Reyburn, H., et al. (2004). Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: A prospective study. British Medical Journal. doi: 10.1136/bmj.38251.658229.55.
  11. Uzochukwu, B., et al. (2010). Willingness to pay for rapid diagnostic tests for the diagnosis and treatment of malaria in southeast Nigeria: Ex post and ex ante. International Journal for Equity in Health, 9, 1.CrossRefGoogle Scholar
  12. World Health Organization. (2010). 2009 World malaria report. Geneva: WHO Press.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.Department of Global Health and PopulationHarvard School of Public HealthBostonUSA
  2. 2.Northeastern UniversityBostonUSA
  3. 3.Brookings InstitutionWashingtonUSA

Personalised recommendations